Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 2/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ILK | Q13418 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12896185 | 0.80 | BCL2L1 (0.39) | APP | |
| SCHEMBL2431221 | 0.79 | HSD17B10 (0.34) | HSD17B10APP | |
| SCHEMBL12896161 | 0.78 | ESR1 (0.40) | — | |
| SCHEMBL12896176 | 0.75 | BCKDK (0.38) | — | |
| SCHEMBL19155499 | 0.72 | LIMK1 (0.42) | HSD17B10APPLIMK1CA2ILK | |
| SCHEMBL13520159 | 0.71 | LIMK1 (0.44) | HSD17B10APPLIMK1CA2ILK | |
| SCHEMBL12732588 | 0.71 | BCL2L1 (0.39) | — | |
| SCHEMBL12896179 | 0.70 | GPR3 (0.46) | — | |
| SCHEMBL12896160 | 0.69 | ALB (0.38) | CA2 | |
| SCHEMBL17232354 | 0.68 | UGT2B7 (0.35) | HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028507-A1 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | CRYSTALGENOMICS, INC. (KR) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028507-A1 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | EGLN3, EGLN2, HIF1A | HSD17B10 659/4885APP 2852/4885LIMK1 4245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.